The Technical Analyst
Prometheus Biosciences, [RXDX]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Prometheus Biosciences, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.31% $28.60
Last updated: 3 jul 2022 - 19:29
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 121.06 mill |
| EPS: | -2.78 |
| P/E: | 0.000 |
| Earnings Date: | May 13, 2021 |
| SharesOutstanding: | 39.20 mill |
| Avg Daily Volume: | 0.490 mill |
| RATING 2022-07-01 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$35.22 (23.15%) $6.62 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $2.06 ( +/- 7.19%) Range: 26.54 - 30.66 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-20 | Marshall Keith W | Buy | 86 582 | Stock Option (Right to Buy) |
| 2022-05-20 | Stenhouse Mark | Buy | 86 582 | Stock Option (Right to Buy) |
| 2022-05-20 | Mckenna Mark C. | Buy | 246 639 | Stock Option (Right to Buy) |
| 2022-05-19 | Szela Mary T | Buy | 20 500 | Stock Option (Right to Buy) |
| 2022-05-19 | Papa Joseph C | Buy | 22 551 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -33.42 |
| Last 100 transactions |
| Buy: 29 536 402 | Sell: 65 624 957 |
Forecast:
16:00 - $28.60
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $28.60
Forecast 2: 16:00 - $28.60
Forecast 3: 16:00 - $28.60
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $28.60 (1.31% ) |
| Volume | 0.189 mill |
| Avg. Vol. | 0.490 mill |
| % of Avg. Vol | 38.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RXDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 28 - 16:58 | buy | $27.52 | N/A | Active |
|---|
RXDX
Latest Press Releases
2022-06-08 08:00:00 - Press Release
Prometheus Biosciences Provides Enrollment Update In Apollo-cd And Artemis-uc Global Phase 2 Studies
- enrollment completed ahead of schedule for apollo-cd phase 2a study of pra023 in crohn's disease patients -
2022-03-30 08:00:00 - Press Release
Prometheus Biosciences Initiates Third Phase 2 Study Of Pra023 For Systemic Sclerosis-associated Interstitial Lung Disease (ssc-ild)
- first therapeutic candidate for the treatment of ssc-ild targeting both key fibrotic and inflammatory pathways -
2021-12-07 07:00:00 - Press Release
Prometheus Biosciences Reports Positive Topline Phase 1 Data On Lead Therapeutic Candidate Pra023; Expands Indications To Include Systemic Sclerosis-associated Interstitial Lung Disease (ssc-ild)
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity
2021-11-12 08:00:00 - Press Release
Prometheus Biosciences Reports Third Quarter 2021 Financial Results And Highlights Recent Corporate Progress
- full clinical trial results from phase 1a trial of pra023 and announcement of a third phase 2 indication for pra023 expected in fourth quarter 2021 -
2021-08-05 07:30:00 - Press Release
In Memoriam – Friend, Scientific Innovator, Advisor And Board Chair Dr. Tadataka Yamada Has Passed Away
San diego, aug. 05, 2021 (globe newswire) -- prometheus biosciences, inc. (nasdaq: rxdx), with great sorrow announced today that its chairman of the board, tadataka (tachi) yamada, m.d., kbe, passed away unexpectedly on august 4, 2021.
Latest News
2022-05-12 18:48:34 - Zacks Investment Research
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-02-07 08:00:00 - GlobeNewsWire
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will conduct a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET.
2022-01-18 14:56:30 - Stockmarketcom
Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch
2022-01-05 08:30:00 - GlobeNewsWire
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST.
2021-12-15 13:21:18 - Business Insider
These were the 10 best performing IPOs of 2021 amid a record year for stock market debuts
Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.
2021-12-08 12:53:34 - Stockmarketcom
3 Biotech Stocks To Watch On Pfizer's Latest Omicron Update
2021-12-08 09:33:13 - Seeking Alpha
Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
2021-11-02 15:20:05 - Zacks Investment Research
How to Use New Analyst Coverage to Find Strong Stocks to Buy
One way to find potential winning stocks is to search for companies that recently landed new analyst coverage.
2021-10-12 16:01:00 - GlobeNewsWire
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021 at 11:30 a.m. ET.
2021-10-07 11:26:26 - Pulse2
RXDX Stock: $35 Price Target By Oppenheimer
The shares of Prometheus Biosciences Inc (NASDAQ: RXDX) have received a $35 price target by Oppenheimer. These are the details.